» Articles » PMID: 29971495

Levodopa-induced Dyskinesia: Clinical Features, Incidence, and Risk Factors

Overview
Specialties Neurology
Physiology
Date 2018 Jul 5
PMID 29971495
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Symptoms of Parkinson's disease have been controlled with levodopa for many years; however, motor complications consisting of wearing off of medication effect and dyskinesias tend to occur within a few years of starting levodopa. Motor complications can begin a few months after taking levodopa, with the average time to onset estimated to be 6.5 years. Dyskinesias can be troublesome and require intervention. Levodopa-induced dyskinesia can be composed of a variety of movement disorders including chorea, dystonia, ballism, myoclonus, and akathisia. Based on the clinical pattern, the most common dyskinesia is chorea and choreoathetosis. The clinical manifestations can be divided into three main categories based on their clinical movement patterns and the temporal correlation between the occurrence of dyskinesia and the levodopa dosing: on or peak-dose dyskinesias, biphasic dyskinesias, and Off dyskinesias. Severe cases of dyskinesia have been reported, with the extreme being dyskinesia-hyperpyrexia syndrome. The prevalence of LID has been reported in many studies, but the reported incidence varies. The rate of LID development is from 3 to 94%. The prevalence of LID mainly depends on age at onset, disease duration, and severity, and duration of levodopa therapy. Some of the risk factors for the development of dyskinesia are modifiable. Modifiable risk factors include levodopa dose and body weight. Non-modifiable risk factors include age, gender, duration of disease, clinical subtype, disease progression, disease severity, and genetic factors.

Citing Articles

The design and development of LRRK2 inhibitors as novel therapeutics for Parkinson's disease.

Bai X, Zhu J, Chen Y, Sun H Future Med Chem. 2024; 17(2):221-236.

PMID: 39717965 PMC: 11749465. DOI: 10.1080/17568919.2024.2444875.


Targeting serum response factor (SRF) deactivates ΔFosB and mitigates Levodopa-induced dyskinesia in a mouse model of Parkinson's disease.

Kambey P, Wu J, Liu W, Su M, Buberwa W, Tang C Gene Ther. 2024; 31(11-12):614-624.

PMID: 39384937 DOI: 10.1038/s41434-024-00492-8.


Levodopa-induced dyskinesia: brain iron deposition as a new hypothesis.

Zhang F, Ye Z, Xie Y, Liu M, Zhang L, Zhang J Biometals. 2024; 37(6):1307-1323.

PMID: 39212870 DOI: 10.1007/s10534-024-00628-8.


Exploring causal effects of sarcopenia on risk and progression of Parkinson disease by Mendelian randomization.

Wang T, Geng J, Zeng X, Han R, Huh Y, Peng J NPJ Parkinsons Dis. 2024; 10(1):164.

PMID: 39198455 PMC: 11358304. DOI: 10.1038/s41531-024-00782-3.


Does Delaying Levodopa Prevent Motor Complications in Parkinson's Disease? A Meta-Analysis.

Ramanzini L, Frare J, Camargo L, Silveira J, Jankovic J Mov Disord Clin Pract. 2024; 11(10):1195-1202.

PMID: 39189097 PMC: 11489609. DOI: 10.1002/mdc3.14198.


References
1.
Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian M, Chase T . Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 1998; 50(5):1323-6. DOI: 10.1212/wnl.50.5.1323. View

2.
Pechevis M, Clarke C, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G . Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005; 12(12):956-63. DOI: 10.1111/j.1468-1331.2005.01096.x. View

3.
Schrag A, Ben-Shlomo Y, Brown R, Marsden C, Quinn N . Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality. Mov Disord. 1998; 13(6):885-94. DOI: 10.1002/mds.870130605. View

4.
Comi C, Ferrari M, Marino F, Magistrelli L, Cantello R, Riboldazzi G . Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease. Int J Mol Sci. 2017; 18(2). PMC: 5343779. DOI: 10.3390/ijms18020242. View

5.
Verhagen Metman L, Del Dotto P, Blanchet P, van den Munckhof P, Chase T . Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids. 1999; 14(1-3):75-82. DOI: 10.1007/BF01345246. View